Nanologica AB (NICA) - Net Assets

Latest as of December 2025: Skr22.64 Million SEK ≈ $2.44 Million USD

Based on the latest financial reports, Nanologica AB (NICA) has net assets worth Skr22.64 Million SEK (≈ $2.44 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr88.11 Million ≈ $9.48 Million USD) and total liabilities (Skr65.47 Million ≈ $7.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Nanologica AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr22.64 Million
% of Total Assets	25.7%
Annual Growth Rate	14.75%
5-Year Change	-56.11%
10-Year Change	2.77%
Growth Volatility	653.28

Nanologica AB - Net Assets Trend (2012–2025)

This chart illustrates how Nanologica AB's net assets have evolved over time, based on quarterly financial data. Also explore Nanologica AB total assets for the complete picture of this company's asset base.

Annual Net Assets for Nanologica AB (2012–2025)

The table below shows the annual net assets of Nanologica AB from 2012 to 2025. For live valuation and market cap data, see Nanologica AB (NICA) total market value.

Year	Net Assets	Change
2025-12-31	Skr22.64 Million ≈ $2.44 Million	-69.45%
2024-12-31	Skr74.11 Million ≈ $7.98 Million	+4004.74%
2023-12-31	Skr-1.90 Million ≈ $-204.26K	-102.59%
2022-12-31	Skr73.16 Million ≈ $7.87 Million	+41.79%
2021-12-31	Skr51.60 Million ≈ $5.55 Million	-44.50%
2020-12-31	Skr92.97 Million ≈ $10.00 Million	+2155.89%
2019-12-31	Skr4.12 Million ≈ $443.48K	-82.62%
2018-12-31	Skr23.71 Million ≈ $2.55 Million	+1123.13%
2017-12-31	Skr1.94 Million ≈ $208.60K	-91.20%
2016-12-31	Skr22.03 Million ≈ $2.37 Million	-8.72%
2015-12-31	Skr24.14 Million ≈ $2.60 Million	+195.79%
2014-12-31	Skr8.16 Million ≈ $878.25K	-23.43%
2013-12-31	Skr10.66 Million ≈ $1.15 Million	+181.53%
2012-12-31	Skr3.79 Million ≈ $407.43K	--

Equity Component Analysis

This analysis shows how different components contribute to Nanologica AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 41752281100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr4.51 Million	19.90%
Other Components	Skr442.05 Million	1952.10%
Total Equity	Skr22.64 Million	100.00%

Nanologica AB Competitors by Market Cap

The table below lists competitors of Nanologica AB ranked by their market capitalization.

Company	Market Cap
Davis Commodities Limited Ordinary Shares NASDAQ:DTCK	$5.12 Million
Tarapur Transformers Limited NSE:TARAPUR	$5.13 Million
Avricore Health Inc V:AVCR	$5.13 Million
Vestand Inc. NASDAQ:VSTD	$5.13 Million
Hubify Ltd AU:HFY	$5.12 Million
Maple Peak Investments Inc V:MAP	$5.12 Million
Mint Corp V:MIT	$5.12 Million
Auction Technology Group PLC LSE:ATG	$5.12 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Nanologica AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 74,112,000 to 22,645,000, a change of -51,467,000 (-69.4%).
Net loss of 51,289,000 reduced equity.
New share issuances of 38,000 increased equity.
Other comprehensive income increased equity by 999.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-51.29 Million	-226.49%
Share Issuances	Skr38.00K	+0.17%
Other Comprehensive Income	Skr999.00	+0.0%
Other Changes	Skr-217.00K	-0.96%
Total Change	Skr-	-69.44%

Book Value vs Market Value Analysis

This analysis compares Nanologica AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.08x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.16x to 2.08x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	Skr3.39	Skr0.53	x
2013-12-31	Skr7.40	Skr0.53	x
2014-12-31	Skr2.38	Skr0.53	x
2015-12-31	Skr6.61	Skr0.53	x
2016-12-31	Skr5.84	Skr0.53	x
2017-12-31	Skr0.42	Skr0.53	x
2018-12-31	Skr1.43	Skr0.53	x
2019-12-31	Skr0.24	Skr0.53	x
2020-12-31	Skr3.84	Skr0.53	x
2021-12-31	Skr1.82	Skr0.53	x
2022-12-31	Skr2.40	Skr0.53	x
2023-12-31	Skr-0.05	Skr0.53	x
2024-12-31	Skr1.50	Skr0.53	x
2025-12-31	Skr0.26	Skr0.53	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Nanologica AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -226.49%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -242.77%
• Asset Turnover: 0.24x
• Equity Multiplier: 3.89x
Recent ROE (-226.49%) is below the historical average (-195.75%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	-133.01%	-141.30%	0.55x	1.71x	Skr-5.41 Million
2013	-105.89%	-212.36%	0.34x	1.46x	Skr-11.01 Million
2014	-180.42%	-894.90%	0.08x	2.40x	Skr-15.54 Million
2015	-59.20%	-438.02%	0.10x	1.36x	Skr-16.70 Million
2016	-101.93%	-1122.76%	0.06x	1.45x	Skr-24.66 Million
2017	-1036.69%	-772.94%	0.10x	13.37x	Skr-20.29 Million
2018	-88.11%	-503.92%	0.12x	1.45x	Skr-23.26 Million
2019	-521.07%	-209.97%	0.24x	10.26x	Skr-21.89 Million
2020	-26.70%	-153.86%	0.11x	1.57x	Skr-34.12 Million
2021	-97.16%	-388.20%	0.13x	1.91x	Skr-55.29 Million
2022	-75.30%	-3542.77%	0.01x	2.11x	Skr-62.41 Million
2023	0.00%	-5208.39%	0.02x	0.00x	Skr-74.97 Million
2024	-88.55%	-451.43%	0.10x	1.93x	Skr-73.04 Million
2025	-226.49%	-242.77%	0.24x	3.89x	Skr-53.55 Million

Industry Comparison

This section compares Nanologica AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $165,054,194
Average return on equity (ROE) among peers: -81.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Nanologica AB (NICA)	Skr22.64 Million	-133.01%	2.89x	$5.12 Million
2cureX AB (2CUREX)	$74.34 Million	-25.47%	0.06x	$4.90 Million
Ascelia Pharma AB (publ) (ACE)	$74.33 Million	-147.03%	0.17x	$40.96 Million
AcouSort AB (ACOU)	$15.58 Million	-57.51%	0.12x	$8.97 Million
Active Biotech AB (ACTI)	$188.64 Million	-118.73%	1.64x	$17.19 Million
Alzinova AB (ALZ)	$20.63 Million	-16.51%	0.08x	$4.97 Million
AlzeCure Pharma (ALZCUR)	$182.01 Million	-28.02%	0.03x	$18.18 Million
Annexin Pharmaceuticals AB (ANNX)	$18.81 Million	-234.16%	0.42x	$11.24 Million
Alligator Bioscience AB (ATORX)	$68.52 Million	-112.06%	0.43x	$14.33 Million
BioInvent International AB (BINV)	$219.00 Million	-63.86%	0.22x	$155.44 Million
BioArctic AB (publ) (BIOA-B)	$788.68 Million	-15.19%	0.14x	$2.59 Billion

About Nanologica AB

ST:NICA Sweden Biotechnology

Market Cap

$5.12 Million

Skr47.60 Million SEK

Market Cap Rank

#28320 Global

#640 in Sweden

Share Price

Skr0.53

Change (1 day)

+0.75%

52-Week Range

Skr0.35 - Skr1.98

All Time High

Skr19.15